Sclerotherapy Market Size, Share, Growth – By Agents, By Therapy, By Application, Global Forecast, 2025 – 2034

Sclerotherapy Market Size

The global sclerotherapy market size was valued at USD 1.3 billion in 2024 and is projected to exhibit 6.1% CAGR from 2025 to 2034. The increasing prevalence of vascular disorders, rising demand for minimally invasive therapeutic procedures, regulatory approval of advanced sclerosants, and the growing adoption of sclerotherapy as a cost-effective alternative to surgery are driving revenue growth in the market.
 

Sclerotherapy is a simple, minimally invasive procedure gaining popularity among patients seeking non-surgical treatments for vascular disorders. This procedure does not require general anesthesia, offers quicker recovery, reduces patient risks, and provides cost-effective benefits compared to traditional surgery. For example, the typical cost of varicose vein treatment through sclerotherapy ranges from USD 300 to 500, while surgical treatments, such as ambulatory phlebectomy, can cost between USD 2,000 and 4,000. As a result, many patients prefer the minimally invasive sclerotherapy over surgery, driving global market growth.
 

Sclerotherapy is a minimally invasive procedure used to treat varicose and spider veins. During this procedure, a healthcare provider injects a chemical solution or foam (called a sclerosing agent) into the affected vein, causing the vein to collapse and stick together. Over time, the vein turns into scar tissue, which the body absorbs, making the vein disappear.
 

Sclerotherapy Market Trends

Several key trends, driven by technological advancements, patient preferences, and evolving healthcare delivery, are shaping the growth and development of the market.
 

• Artificial Intelligence (AI) is transforming sclerotherapy by providing enhanced diagnostics and treatment strategies. Medical professionals are using AI-driven imaging systems to analyze vein structures, identify abnormalities, and determine the most effective injection points. These innovations have reduced variability among practitioners and improved treatment precision. Additionally, AI tools are being employed post-treatment to monitor recovery, quickly detect complications, and improve long-term patient outcomes.
   
• The combination of laser therapy and sclerotherapy is increasingly popular for treating mixed vein sizes and complex venous conditions. Medical lasers are effective for smaller veins, while sclerotherapy addresses larger veins. This hybrid approach improves efficacy and reduces the number of treatment sessions, as the two methods complement each other. It is especially beneficial for patients seeking comprehensive vein treatment with quicker recovery and better cosmetic results.
   
• The adoption of robotic systems to enhance precision in sclerotherapy is gaining traction worldwide. Robotic systems automate the injection process, ensuring the correct amount of sclerosant is administered in the right location. This reduces errors and ensures more reliable outcomes.
   
• Manufacturers are also enhancing robotic systems to allow remote control or full automation of treatments, which is particularly useful for complex or high-volume cases.
   
• Additionally, 3D medical imaging devices are helping healthcare providers create detailed images of a patient's venous system, enabling precise treatment planning.
   
• This technology is particularly useful in complex cases, helping to identify hidden or hard-to-reach veins. By offering a clear view of the vein structure, 3D imaging ensures accurate sclerosant delivery and improves treatment outcomes.
   

Sclerotherapy Market Analysis

Based on agents, the sclerotherapy market is segmented into detergents, chemical irritants, and osmotic agents. Detergents segment dominates the market with a share of 68.1% in 2024.
 

• The detergents segment leads the market due to their efficacy, safety profile, and versatility compared to other types of sclerosing agents. Detergents such as polidocanol and sodium tetradecyl sulfate are commonly used for both cosmetic and medical treatments of varicose and spider veins.
   
• These agents are approved by regulatory bodies like the U.S. FDA, enhancing their credibility and widespread use.
   
• Detergents also have a lower risk of complications, such as allergic reactions or hyperpigmentation, compared to osmotic agents and chemical irritants.
   

Based on therapy, the sclerotherapy market is segmented into liquid sclerotherapy, ultrasound sclerotherapy, foam sclerotherapy, and other therapies. Liquid sclerotherapy segment dominates the market with a share of 46.9% in 2024.
 

• Liquid sclerotherapy dominates due to its versatility, cost-effectiveness, and suitability for treating smaller veins like spider veins. It is also more affordable than foam-based or advanced treatments, making it more accessible to patients and clinics with budget constraints.
   
• Moreover, liquid sclerotherapy carries a reduced risk of complications, such as embolization, when used for smaller veins, making it a safer option. It is also a straightforward procedure that requires minimal preparation compared to foam or other therapies.

Based on application, the sclerotherapy market is segmented into varicose veins, hemorrhoids, malformed lymph vessels, hydroceles, and other applications. The varicose veins segment held a dominating share of 64.8% in the market in 2024.
 

• Varicose veins affect a significant portion of the population, particularly older adults, pregnant women, and individuals with sedentary lifestyles or jobs requiring prolonged standing. According to a December 2023 study by the Multidisciplinary Digital Publishing Institute, between 10% and 30% of people worldwide suffer from lower extremity varicose veins. The high global prevalence of varicose veins drives the demand for effective treatments like sclerotherapy.
   
• Additionally, an increasing number of patients are opting for minimally invasive procedures such as sclerotherapy, which offers faster recovery, less pain, and reduced downtime compared to traditional surgery, further boosting the demand for sclerotherapy in varicose vein treatment.

In 2024, the U.S. led the North American sclerotherapy market, generating a revenue of about USD 483 million.
 

• The high prevalence of vascular diseases in the U.S. is a key driver of revenue growth in the market. According to the 2024 varicose vein statistics published by the Chicago Vein Institute, superficial venous disease affects 50% of the population aged 50 and older in the U.S., creating significant demand for sclerotherapy and related treatments.
   
• Furthermore, the U.S. has a well-established healthcare system with specialized clinics and hospitals equipped to perform sclerotherapy, along with access to advanced diagnostic tools like ultrasound, enhancing the accuracy and effectiveness of treatments.
   

The UK is set to see a robust expansion in its sclerotherapy market from 2025 - 2034.
 

• Growing awareness of non-invasive treatment options for vascular conditions is driving market expansion in the UK. A July 2022 study published by the National Center for Biotechnology Information reported a 60% rise in endovenous procedures like sclerotherapy between 2006 and 2021, while the rate of surgical procedures declined.
   
• Additionally, public health initiatives in the UK, particularly through the NHS Long Term Plan, are promoting early diagnosis and intervention, fueling the demand for alternative therapies like sclerotherapy.
   

Japan's sclerotherapy market is set for lucrative growth from 2025 to 2034.
 

• Japan’s advanced healthcare system, combined with increasing healthcare access, supports the widespread use of treatments like sclerotherapy for venous disorders.
   
• The country’s aging population, with about 30% of the population aged 65 and above in 2023 (according to the World Bank Group), has led to a rise in age-related conditions such as varicose veins.
   
• As a result, the demand for minimally invasive treatments like sclerotherapy has increased.
   

Saudi Arabia's sclerotherapy market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia’s significant investment in its healthcare system, coupled with the increasing prevalence of venous disorders like varicose veins, is driving the demand for sclerotherapy.
   
• Factors such as obesity, lack of physical activity, and pregnancy contribute to the rise in venous disorders in the country. According to a May 2024 study by the National Center for Biotechnology Information, the incidence of varicose veins in Saudi Arabia was 62%, resulting in strong demand for sclerotherapy treatments.
   

Sclerotherapy Market Share

The market is relatively fragmented, with a wide range of players involved across various segments, including the sclerosant manufacturers, clinical providers, and specialized clinics offering treatments. This fragmentation is driven by the diversity of products, technologies, and treatment approaches available for the management of venous disorders. Large companies offer extensive portfolios and have a global reach. Whereas smaller companies often specialize in certain aspects of sclerotherapy or focus on niche markets, offering innovative solutions or unique products.
 

Sclerotherapy Market Companies

Some of the eminent market participants operating in the sclerotherapy industry include:

• AngioDynamics
• Bioniche Pharma Group
• Boston Scientific Corporation
• Changan Tianyu group
• Chemische Fabrik Kreussler 
• Cook Medical
• Endo-Flex (Meditek Systems)
• Erbe Elektromedizin
• LGM Pharma
• Medtronic
• MTW ENDOSKOPIE
• Omega Labs
• Perrigo Company
• Samarth Life Sciences
• Troikaa Pharmaceuticals
   

Sclerotherapy Industry News:

• In December 2023, Chemische Fabrik Kreussler announced a partnership with S.T.D. Pharmaceutical Products to globally produce, market, and distribute Fibrovein. S.T.D. Pharmaceutical Products sought a strategic partner to enhance synergies in the production and worldwide marketing of Fibrovein, for use in sclerotherapy.
   

The sclerotherapy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Agents

• Detergents
• Chemical irritants
• Osmotic agents

Market, By Therapy

• Liquid sclerotherapy
• Ultrasound sclerotherapy
• Foam sclerotherapy
• Other therapies

Market, By Application

• Varicose veins
• Hemorrhoids
• Malformed lymph vessels
• Hydroceles
• Other applications

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE